ACADIA Pharmaceuticals Inc.

About: ACADIA Pharmaceuticals Inc. is a company organization based out in San Diego, California, United States. It is known for research contribution in the topics: Pimavanserin & Receptor. The organization has 260 authors who have published 276 publications receiving 8418 citations.

Assessment of Learning and Memory Using the Autoshaping of Operant Responding in Mice

Abstract: This unit describes the use of an automated procedure for developing an operant response (“autoshaping”) in the mouse. The method has applications in the study of the acquisition of behavior (learning) as well as for the assessment of memory or retention of that task. Keywords: mouse; autoshaping; operant responding; learning; memory; operant conditioning; respondent conditioning

Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.

Abstract: In a post hoc analysis, the effect of pimavanserin on anxious depression was determined from CLARITY, a randomized, double-blind, placebo-controlled study in patients with major depression and an inadequate response to previous therapy Patients were randomized in a 3:1 ratio to placebo or pimavanserin 34 mg daily added to ongoing antidepressant therapy At 5 weeks, placebo nonresponders were rerandomized to placebo or pimavanserin for an additional 5 weeks Mean change from baseline to week 5 for the Hamilton depression rating scale (HAMD) anxiety/somatization (AS) factor was examined for all patients and those with a score ≥7 at baseline Least squares (LS) mean [standard error (SE)] difference between placebo and pimavanserin for the AS factor score was -15 (041) [95% confidence interval (CI) -24 to -07; P = 00003; effect size: 0634] Among patients with an AS factor score ≥7 at baseline, LS mean (SE) difference was -22 (066) (95% CI -35 to -09; P = 00013; effect size: 0781) Response rates (≥50% reduction in HAMD-17 from baseline) were 224 and 552% (P = 00012) and remission rates (HAMD-17 total score <7) were 53 and 241% (P = 00047), respectively, with placebo and pimavanserin among patients with a baseline AS factor score ≥7 Among patients with anxious major depressive disorder at baseline, adjunctive pimavanserin was associated with a significant improvement

Chiral Dihydrobenzofuran Acids Show Potent Retinoid X Receptor–Nuclear Receptor Related 1 Protein Dimer Activation

Abstract: The nuclear receptor Nurr1 can be activated by RXR via heterodimerization (RXR-Nurr1) and is a promising target for treating neurodegenerative diseases. We herein report the enantioselective synthesis and SAR of sterically constricted benzofurans at RXR. The established SAR, using whole cell functional assays, lead to the full agonist 9a at RXR (pEC50 of 8.2) and RXR-Nurr1. The X-ray structure shows enantiomeric discrimination where 9a optimally addresses the ligand binding pocket of RXR.